Kalaris Therapeutics Inc. 最新财报数据显示,该公司第一季度营业费用为1183.3万美元,导致同期营业亏损达到同等数额。
Kalaris Therapeutics Inc. 最新财报数据显示,该公司第一季度营业费用为1183.3万美元,导致同期营业亏损达到同等数额。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.